<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112838</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-050</org_study_id>
    <secondary_id>2014-000331-16</secondary_id>
    <nct_id>NCT02112838</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fostamatinib is safe and effective in the
      treatment of IgA Nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of proteinuria as measured by spot urine protein/creatinine ratio (sPCR)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 150 mg</intervention_name>
    <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 100 mg</intervention_name>
    <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
    <arm_group_label>Fostamatinib 100 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal biopsy findings consistent with IgA nephropathy

          -  Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an
             Angiotensin II Receptor Blocker (ARB) for at least 90 days at the maximum approved
             (or tolerated) dose

          -  Proteinuria &gt; 1 gm/day at diagnosis of IgA nephropathy and Proteinuria &gt; 0.50 gm/day
             at the second Screening Visit

          -  Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other
             anti-hypertensive agents

        Exclusion Criteria:

          -  Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab.

          -  Use of &gt; 15 mg/day prednisone (or other corticosteroid equivalent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rigel Pharmaceuticals, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rigel Pharmaceuticals, Inc.</last_name>
    <email>clinicaltrials@rigel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lafayette, MD</last_name>
      <phone>650-498-6063</phone>
    </contact>
    <investigator>
      <last_name>Richard Lafayette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates PC, University Hospital, Professional Center 1</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Williamson, MD</last_name>
      <phone>706-722-5843</phone>
    </contact>
    <investigator>
      <last_name>Don Williamson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Rovin, MD</last_name>
      <phone>614-293-4997</phone>
    </contact>
    <investigator>
      <last_name>Brad Rovin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Tumlin, MD</last_name>
      <phone>423-648-7697</phone>
    </contact>
    <investigator>
      <last_name>James Tumlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Rosenkranz, MD</last_name>
      <phone>0043 316 38512170</phone>
    </contact>
    <investigator>
      <last_name>Alexander Rosenkranz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Nephrology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gere Sunder-Plassmann, Prof. Dr.</last_name>
      <phone>0043 1 40400-4217</phone>
    </contact>
    <investigator>
      <last_name>Gene Sunder-Plassmann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurtemberberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Sommerer, MD</last_name>
      <phone>0049 6221 5637359</phone>
    </contact>
    <investigator>
      <last_name>Claudia Sommerer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Vielhauer, MD</last_name>
      <phone>0049 89 4400 53217</phone>
    </contact>
    <investigator>
      <last_name>Volker Vielhauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hohenstein, MD</last_name>
      <phone>0049 35145818639</phone>
    </contact>
    <investigator>
      <last_name>Bernd Hohenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Busch, MD</last_name>
      <phone>0049 6221 5637359</phone>
    </contact>
    <investigator>
      <last_name>Martin Busch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Sha Tin</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheuk-Chun Szeto, MD</last_name>
      <phone>852 26323878</phone>
    </contact>
    <investigator>
      <last_name>Cheuk-Chun Szeto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sydney Tang, MD</last_name>
      <phone>852 22553879</phone>
    </contact>
    <investigator>
      <last_name>Sydney Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University of Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiu- Ching Huang, MD</last_name>
      <phone>886-958-083-166</phone>
    </contact>
    <investigator>
      <last_name>Chiu- Ching Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>School of Medicine, Chang Gung University, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Chin Lai, MD</last_name>
      <phone>886-3 3281200</phone>
    </contact>
    <investigator>
      <last_name>Ping Chin Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Willcocks, MD</last_name>
      <phone>0044 1223 217259</phone>
    </contact>
    <investigator>
      <last_name>Lisa Willcocks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Fraser, MD</last_name>
      <phone>0044 2920 748 449</phone>
    </contact>
    <investigator>
      <last_name>Donald Fraser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Barratt, MD</last_name>
      <phone>0044 2588043</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Barratt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Gale, MD, PhD</last_name>
      <phone>0044 207830 2695</phone>
    </contact>
    <investigator>
      <last_name>Danny Gale, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Tam, MD</last_name>
      <phone>0044 2083832354</phone>
    </contact>
    <investigator>
      <last_name>Frederick Tam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Brown, MD</last_name>
      <phone>0044 191 241 8632</phone>
    </contact>
    <investigator>
      <last_name>Alison Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IGA Glomerulonephritis</keyword>
  <keyword>Nephritis, IGA Type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
